Premium
99m Tc Labeled Biotin Conjugate in a Tumor “Pretargeting” Approach with Monoclonal Antibodies
Author(s) -
Koch Peter,
Mäcke Helmut Robert
Publication year - 1992
Publication title -
angewandte chemie international edition in english
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 0570-0833
DOI - 10.1002/anie.199215071
Subject(s) - pretargeting , avidin , biotin , conjugate , monoclonal antibody , chemistry , in vivo , monoclonal , in vitro , streptavidin , antibody , radioimmunotherapy , biochemistry , medicine , biology , immunology , mathematical analysis , mathematics , microbiology and biotechnology
Very stable in vitro and in vivo , the complex of 99m Tc and the biotin derivative 1 shows, like biotin, a high affinity for the glycoprotein avidin. It was successfully used to diagnose brain tumors when the patients were treated three days previously with an unlabeled conjugate of a tumor‐specific monoclonal antibody and avidin.